Citigroup initiated coverage on Amarin (NASDAQ: AMRN ) with a Buy rating and a $20 price target. Citigroup commented, "The overhang from the delayed 3 vs. 5 year FDA market exclusivity decision for AMRN's cardiovascular drug, Vascepa, has pressured the company's valuation towards our view of a near “worst